NASDAQ:LGVN Longeveron (LGVN) Stock Price, News & Analysis $2.69 +0.13 (+5.08%) (As of 10:30 AM ET) Add Compare Share Share Today's Range$2.52▼$2.8650-Day Range$1.57▼$4.5552-Week Range$0.77▼$35.60Volume712,073 shsAverage Volume5.03 million shsMarket Capitalization$17.08 millionP/E RatioN/ADividend YieldN/APrice Target$10.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Longeveron alerts: Email Address Longeveron MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside290.6% Upside$10.00 Price TargetShort InterestHealthy31.36% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.13Based on 10 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($3.67) to ($2.71) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.73 out of 5 starsMedical Sector412th out of 924 stocksPharmaceutical Preparations Industry185th out of 426 stocks 3.5 Analyst's Opinion Consensus RatingLongeveron has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageLongeveron has only been the subject of 1 research reports in the past 90 days.Read more about Longeveron's stock forecast and price target. Previous Next 4.0 Short Interest Percentage of Shares Shorted31.36% of the float of Longeveron has been sold short.Short Interest Ratio / Days to CoverLongeveron has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Longeveron has recently decreased by 37.27%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldLongeveron does not currently pay a dividend.Dividend GrowthLongeveron does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for LGVN. Previous Next 2.3 News and Social Media Coverage News SentimentLongeveron has a news sentiment score of 0.13. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Longeveron this week, compared to 1 article on an average week.Search InterestOnly 10 people have searched for LGVN on MarketBeat in the last 30 days. This is a decrease of -44% compared to the previous 30 days.MarketBeat Follows18 people have added Longeveron to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Longeveron insiders have not sold or bought any company stock.Percentage Held by Insiders19.12% of the stock of Longeveron is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 10.01% of the stock of Longeveron is held by institutions.Read more about Longeveron's insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Longeveron are expected to grow in the coming year, from ($3.67) to ($2.71) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Longeveron is -0.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Longeveron is -0.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLongeveron has a P/B Ratio of 0.96. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Longeveron's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Insiders Exposed$5k to $1.3m in just 3 tradesIt doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.Register for the imminent briefing here. About Longeveron Stock (NASDAQ:LGVN)Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors. It is conducting Phase 1, Phase 1/2, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer's disease, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is headquartered in Miami, Florida.Read More LGVN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart LGVN Stock News HeadlinesAugust 20 at 2:20 AM | americanbankingnews.comHC Wainwright Weighs in on Longeveron Inc.'s Q3 2024 Earnings (NASDAQ:LGVN)August 17, 2024 | americanbankingnews.comLongeveron (NASDAQ:LGVN) Earns Buy Rating from HC WainwrightAugust 22, 2024 | TradingTips (Ad)5 stocks that can double in 2024You still have time to access the 5 Stocks that Can Double in 2024 report for free.August 15, 2024 | markets.businessinsider.comBuy Rating Reaffirmed for Longeveron on Strong Clinical Trial Prospects and Regulatory AdvantagesAugust 15, 2024 | seekingalpha.comLongeveron, Inc. (LGVN) Q2 2024 Earnings Call TranscriptAugust 15, 2024 | msn.comLGVN Solidifies Financials so Treatment Can AdvanceAugust 12, 2024 | americanbankingnews.comLongeveron (LGVN) Set to Announce Quarterly Earnings on WednesdayAugust 1, 2024 | investorplace.comThe Top 3 Small-Cap Stocks to Buy Now: Summer 2024August 22, 2024 | TradingTips (Ad)5 stocks that can double in 2024You still have time to access the 5 Stocks that Can Double in 2024 report for free.July 29, 2024 | investorplace.comLongeveron (LGVN) Stock Pops on Phase 2 Trial UpdatesJuly 28, 2024 | globenewswire.comLongeveron® Presents Study Results from CLEAR MIND Phase 2a Clinical Trial of Lomecel-B™ in Mild Alzheimer's Disease at the Alzheimer's Association International Conference® (AAIC)July 27, 2024 | finance.yahoo.comBullish Longeveron Insiders Loaded Up On US$734.3k Of StockJuly 19, 2024 | globenewswire.comLongeveron Announces Closing of $9.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesJuly 18, 2024 | globenewswire.comLongeveron Announces $9.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesJuly 18, 2024 | globenewswire.comLongeveron Announces $9.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesJuly 17, 2024 | investorplace.comLGVN Stock Alert: Longeveron Pops 18% on FDA Fast-Track DesignationJuly 10, 2024 | investorplace.comWhy Is Longeveron (LGVN) Stock Up 53% Today?July 10, 2024 | globenewswire.comLongeveron® Announces U.S. FDA Grants Lomecel-B™ Regenerative Medicine Advanced Therapy (RMAT) Designation for the Treatment of Mild Alzheimer's DiseaseSee More Headlines Receive LGVN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Longeveron and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/14/2024Today8/22/2024Next Earnings (Estimated)11/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:LGVN CUSIPN/A CIK1721484 Webwww.longeveron.com Phone305-302-7158FaxN/AEmployees20Year FoundedN/APrice Target and Rating Average Stock Price Target$10.00 High Stock Price Target$10.00 Low Stock Price Target$10.00 Potential Upside/Downside+290.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($9.61) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-21,410,000.00 Net Margins-2,129.24% Pretax Margin-2,129.24% Return on Equity-300.96% Return on Assets-164.96% Debt Debt-to-Equity RatioN/A Current Ratio0.71 Quick Ratio0.71 Sales & Book Value Annual Sales$1.23 million Price / Sales13.22 Cash FlowN/A Price / Cash FlowN/A Book Value$2.68 per share Price / Book0.96Miscellaneous Outstanding Shares6,349,000Free Float5,135,000Market Cap$16.25 million OptionableNot Optionable Beta0.43 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesDr. Joshua Michael Hare FACC (Age 61)M.D., Co-Founder, Chief Science Officer & Chairman Comp: $74kMr. Mohamed Wa'el Ahmed Hashad (Age 62)CEO & Director Comp: $781.56kMs. Lisa A. Locklear M.B.A. (Age 62)Executive VP & CFO Comp: $248.38kMr. Paul T. Lehr J.D. (Age 56)International Executive Director, General Counsel & Secretary Comp: $554.05kDr. Dan Gincel Ph.D. (Age 53)Senior Vice President of Strategic Collaborations & Scientific Affairs Dr. Nataliya Agafanova M.D. (Age 54)Chief Medical Officer Ms. Elly Ryu (Age 42)VP & Corporate Controller More ExecutivesKey CompetitorsVincerx PharmaNASDAQ:VINCLisata TherapeuticsNASDAQ:LSTABrainstorm Cell TherapeuticsNASDAQ:BCLIPluriNASDAQ:PLURMural OncologyNASDAQ:MURAView All CompetitorsInsiders & InstitutionsRenaissance Technologies LLCBought 146,700 shares on 8/9/2024Ownership: 2.311%Rock SofferBought 31,915 shares on 4/11/2024Total: $75,000.25 ($2.35/share)Mohamed Wa'el Ahmed HashadBought 10,638 shares on 4/11/2024Total: $24,999.30 ($2.35/share)Joshua HareBought 106,383 shares on 4/10/2024Total: $250,000.05 ($2.35/share)Cathy RossBought 500 shares on 1/10/2024Total: $6,550.00 ($13.10/share)View All Insider TransactionsView All Institutional Transactions LGVN Stock Analysis - Frequently Asked Questions How have LGVN shares performed this year? Longeveron's stock was trading at $13.60 at the start of the year. Since then, LGVN stock has decreased by 81.2% and is now trading at $2.56. View the best growth stocks for 2024 here. How were Longeveron's earnings last quarter? Longeveron Inc. (NASDAQ:LGVN) issued its quarterly earnings results on Tuesday, May, 14th. The company reported ($1.61) earnings per share for the quarter, topping analysts' consensus estimates of ($2.01) by $0.40. The business earned $0.55 million during the quarter, compared to the consensus estimate of $0.12 million. Longeveron had a negative net margin of 2,129.24% and a negative trailing twelve-month return on equity of 300.96%. When did Longeveron's stock split? Longeveron shares reverse split before market open on Wednesday, March 27th 2024. The 1-10 reverse split was announced on Wednesday, March 27th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, March 27th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. When did Longeveron IPO? Longeveron (LGVN) raised $30 million in an initial public offering (IPO) on Friday, February 12th 2021. The company issued 2,700,000 shares at $10.00-$12.00 per share. Kingswood Capital Markets and Alexander Capital L.P. served as the underwriters for the IPO. Who are Longeveron's major shareholders? Top institutional shareholders of Longeveron include Renaissance Technologies LLC (2.31%). Insiders that own company stock include Joshua Hare, Rock Soffer, Mohamed Wa'el Ahmed Hashad, James Clavijo, Jeffrey Pfeffer, Cathy Ross, Paul T Lehr and Geoff Green. View institutional ownership trends. How do I buy shares of Longeveron? Shares of LGVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:LGVN) was last updated on 8/22/2024 by MarketBeat.com Staff From Our PartnersAir Force quietly working with sub $10 stock on new techThere is a little-known energy technology stock that has made an incredible breakthrough… Which could becom...DTI | SponsoredTrump is sounding the alarmEurope is one of the latest to release a central bank digital currency and along with it, new cash rules. Chri...Preserve Gold | SponsoredThis Crypto Is Set to Explode in AugustWith the 2024 Bitcoin Halving, there's a potential HUGE bull run for altcoins. While everyone's chasing the...Crypto 101 Media | SponsoredUS developing “superweapon” to defeat China and Russia?Our new superweapon is a gift to every patriot. I predict the devastating new tech behind this weapon will cre...Paradigm Press | SponsoredSilver Grab of the Decade?In a groundbreaking move, J.P. Morgan now possesses the largest amount of physical silver in recorded history…...Colonial Metals | SponsoredAmazon coin set to soar 25X – starting August 19thChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredAlex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time ...The Oxford Club | SponsoredThis One stock is all you need...What if you could ignore 99% of the stock market... And retire on just ONE ticker?Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Longeveron Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Longeveron With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
